Blincyto
As listed in the register: Blincyto 38,5mcg de polvo para concentrado y solucion para solucion para perfusion
38,5 microgramos · polvo para concentrado y solución para solución para perfusion
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Blinatumomab
- Made by
- Amgen Europe B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (BLINCYTO). It describes the substance, not this exact product.
Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells.
It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells.
Negligible amounts of blinatumomab were excreted in the urine at the tested clinical doses.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-04-14
Safety of the active substance
From the US prescribing label for the same active substance (BLINCYTO). It describes the substance, not this exact product.
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.
- BLINCYTO is contraindicated in patients with known hypersensitivity to blinatumomab or to any component of the product formulation.
- Known hypersensitivity to blinatumomab or to any component of the product formulation.
The most common adverse reactions (≥ 20%) to BLINCYTO in this pooled population were pyrexia, infusion-related reactions, headache, infection, musculoskeletal pain, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
France1 matching products
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Amgen Europe B.V. |
|---|---|
| Active substance | Blinatumomab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 38,5 microgramos |
| Form | polvo para concentrado y solución para solución para perfusion |
| Classification | L01FX07 · Cancer treatments and immune-system medicines |
| Route | vía intravenosa |
| Marketed | Yes, according to the register |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | Blincyto 38,5mcg de polvo para concentrado y solucion para solucion para perfusion |
| Nº Registro | 1151047001 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.